₹ 2,343.94 Cr
2.0%
S&P BSE Healthcare TRI
INF740KA1LE6
100.0
100.0
500
Jay Kothari, Chirag Dagli
Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
---|---|---|---|
DSP Healthcare Fund - Regular Plan - IDCW | 48.22 | 15.33 | 26.37 |
S&P BSE Healthcare TRI | 52.62 | 13.64 | 22.27 |
Equity
Debt
Others
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Company | Holdings (%) |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.06 |
Ipca Laboratories Ltd. | 9.17 |
Suven Pharmaceuticals Ltd. | 8.15 |
Cipla Ltd. | 7.67 |
Lupin Ltd. | 7.67 |
Alembic Pharmaceuticals Ltd. | 6.07 |
Apollo Hospitals Enterprise Ltd. | 4.72 |
Concord Biotech Ltd. | 4.44 |
Zydus Lifesciences Ltd. | 4.22 |
Globus Medical Inc | 3.94 |
Sector | Holdings (%) |
---|---|
Healthcare | 96.3 |
Insurance | 1.76 |
Others | 1.03 |
Financial | 0.91 |
Scheme Name | 5Y (%) |
---|---|
DSP Healthcare Reg IDCW | 26.37 |
ICICI Pru Pharma Healthcare and Diagnostics PHD Fund Cum | 25.77 |
ABSL Pharma and Healthcare Reg Gr | 0.0 |
Tata India Pharma & Healthcare Reg Gr | 23.56 |
SBI HEALTHCARE Opportunities Reg Gr | 24.87 |
Nippon India Pharma Fund Gr Gr | 24.41 |
UTI Healthcare Reg Gr | 22.44 |
DSP Healthcare Reg Gr | 27.19 |
Mirae Asset Healthcare Reg Gr | 25.04 |
LIC MF Healthcare Fund Reg Gr | 19.52 |